View clinical trials related to Tumor.
Filter by:In this study, we hope to evaluate the safety of PDT using temoporfin plus endoscopic stents in patients with inoperable bile duct cancers. In addition as a preliminary study we sought to determine if the treatment can reduce tumor volume in the short term.
The primary objective of this study was to assess the effect of cytochrome P450 3A4 enzyme (CYP3A4) induction by rifampicin on the pharmacokinetics (PK) of eribulin mesylate following intravenous (IV) administration in participants with advanced solid tumors. The secondary objectives of this study were to assess the safety of eribulin mesylate when co-administered with rifampicin and assess the safety and activity of eribulin mesylate as a single agent.
This study is a dose escalation study of Ceramide NanoLiposome in patients with advanced solid tumors.
Background: This protocol is designed to have samples from closing protocols transferred to this protocol for long-term storage. The protocol is concerned with the retention of blood, plasma, serum, CSF, aspirates, bone marrow, ascites fluid, urine, saliva, PBMCs, skin, mucosal, tumor and healthy tissue samples from patients with cancer to support basic science and clinical research activities of the Medical Oncology Branch and other intramural Laboratories and Branches at the NIH Clinical Research Center and Center for Cancer Research. Objectives: To allow long-term storage of biospecimens collected during prospective clinical trials in patients with various cancer phenotypes, as needed to support the research activities of the Medical Oncology Branch and other Laboratories and Branches. Eligibility: Samples eligible for long-term retention must be from those who have signed consent for storage and retention of biospecimens. Design: Acquired samples will be barcoded and associated data will be entered into an encrypted computer software system, and securely maintained to protect patient identifiers. Samples are retained and made available to the original PI, or other Investigators with the original PI's permission, following submission and approval of a supplemental research protocol to the IRB or OHSRP.
This study will test a new MRI sequence that measures cerebral blood flow (CBF). Because this technique for measuring CBF is new, there is little information on what the normal values for different regions of the brain should be. Information from the study will be used to establish normative CBF values for the brain, improving the reliable use of this technique for the diagnosis of brain injury or disease.
The primary aim of this study is to identify drivers of cancer by performing comprehensive genetic, proteomic, and metabolomic characterization of patient samples as a basis for understanding the underlying cause of disease.
Sulfatinib (HMPL-012) is a novel oral small molecule that selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 and inhibits FGFR kinase activity has demonstrated potent inhibitory effects on multiple human tumor xenografts. This first-in-human study is conducted to assess the maximum tolerated dose (MTD) and recommended dose for phase II ,to evaluate the pharmacokinetics , safety and preliminary anti-tumor activity of HMPL-012 at single doses and multiple doses .
To evaluate the effectiveness and safety of tenofovir for different treatment duration in preventing HBV relapse in patients with malignancies after receiving chemotherapy and off-treatment of chemotherapy.
The present pilot study is designed to assess the extent to which BOTOX and MYOBLOC cause muscle atrophy in spastic patients. The primary objective is to assess whether there is statistically significant difference in muscle atrophy between the two groups over a one year period.
The purpose of this study is to evaluate the safety and efficacy of CarboFix' Pedicle Screw System in the lumbar spine.